Michelle Burris
Plus aucun poste en cours
Fortune : 166 776 $ au 31/03/2024
Profil
Michelle Griffin Burris served as a Director at Sonus Pharmaceuticals, Inc. from 2004 to 2008.
She also served as a Director at Polynoma LLC from 2012 to 2014.
Prior to that, she was the Chief Financial Officer & Senior Vice President at Corixa Corp.
from 1994 to 2005, and then at Dendreon Corp.
from 2005 to 2006.
From 2006 to 2009, she served as the Chief Financial Officer, Treasurer & SVP at Emergent Product Development Seattle.
She was also the Executive Vice President-Operations at OncoGenex Pharmaceuticals, Inc. from 2013 to 2013.
Additionally, she served as a Director at Virginia Mason Medical Center and Virginia Mason Health System.
Ms. Burris received her undergraduate degree from George Mason University and her MBA from Seattle University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 51 955 ( 0,04% ) | 166 776 $ | 31/03/2024 |
Anciens postes connus de Michelle Burris
| Sociétés | Poste | Fin |
|---|---|---|
Polynoma LLC
 Polynoma LLC BiotechnologyHealth Technology Part of CK Life Sciences International (Holdings), Inc., Polynoma LLC is an immuno-oncology focused biopharmaceutical company headquartered in San Diego, CA. Polynoma's lead asset is a novel polyvalent antigen vaccine, Seviprotimut-L, for the prevention of recurrence of melanoma. The vaccine has been safely administered in more than 1,000 patients. Polynoma is an immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. The private company was founded by Paul A. Hopper. | Director/Board Member | 01/01/2014 |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Director of Finance/CFO | 06/02/2013 |
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Director of Finance/CFO | 17/11/2009 |
Sonus Pharmaceuticals, Inc.
 Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Director/Board Member | 22/08/2008 |
| DENDREON CORPORATION | Director of Finance/CFO | 01/01/2006 |
Formation de Michelle Burris
| George Mason University | Undergraduate Degree |
| Seattle University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHASERX, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Sonus Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Health Technology |
Virginia Mason Medical Center
 Virginia Mason Medical Center Medical/Nursing ServicesHealth Services Virginia Mason Medical Center provides healthcare services. It offers primary and cancer care, diabetes center, digestive disorders, heart care, neurology and neurosurgery, medicine, surgery, urology, and orthopedics and sports. The company was founded by James Tate Mason, John M. Blackford, and Maurice Dwyer in 1920 and is headquartered in Seattle, WA. | Health Services |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
Polynoma LLC
Polynoma LLC BiotechnologyHealth Technology Part of CK Life Sciences International (Holdings), Inc., Polynoma LLC is an immuno-oncology focused biopharmaceutical company headquartered in San Diego, CA. Polynoma's lead asset is a novel polyvalent antigen vaccine, Seviprotimut-L, for the prevention of recurrence of melanoma. The vaccine has been safely administered in more than 1,000 patients. Polynoma is an immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. The private company was founded by Paul A. Hopper. | Health Technology |
Virginia Mason Health System
 Virginia Mason Health System Hospital/Nursing ManagementHealth Services Virginia Mason Health System offers medical services. It is the parent company of a group of affiliated organizations including Virginia Mason Medical Center and the Benaroya Research Institute at Virginia Mason. The firm support the healthcare and research missions of the Virginia Mason Medical Center and Benaroya Research Institute at Virginia Mason. The company was founded in 1920 and is headquartered in Seattle, WA. | Health Services |
